Sector News

Stryker to build new innovation centre in Cork

September 23, 2014
Life sciences
US medical technologies company Stryker is to build a new 44,000 square foot surgical innovation centre in Cork, which will combine all Ireland-based research and new product development activities and support functions within one purpose-built facility. Construction is set to commence in the last months of this year, with completion expected in Q4 2015.
 
“This state-of-the-art facility will drive innovation by giving us the ability to design, develop and test new products in conditions that mimic real life,” Stryker Instruments President Jim Heath said.
 
The innovation centre, which Stryker says will fuel future growth, will focus on the research and development of products, technologies and solutions to reduce surgical procedure time and healthcare costs while improving surgical precision and clinical outcomes in the areas of bone cutting, soft tissue dissection and adjacent areas across a broad spectrum of surgical specialities and procedures. It is being constructed with the support of the IDA.
 
Stryker says the facility will feature state-of-the-art R&D facilities for product design and process development and a customer experience laboratory that will allow engineers and surgeons to test and evaluate new ideas, technology and product designs in a simulated operating room and surgical environment.
Stryker first came to Ireland in 1998 and now employs over 2,200 people at four sites between Cork and Limerick, including over 150 people in research and development.
 
Source: Irish Times

comments closed

Related News

October 23, 2021

Novo Nordisk teams with CVS Health on obesity support program ahead of Wegovy DTC launch

Life sciences

As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.

October 23, 2021

GSK-backed Atreca inks license with Gates Medical Research Institute for malaria monoclonal antibody

Life sciences

The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.

October 23, 2021

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.

Send this to a friend